drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00581 | DB01001 | 355 | 688 | [
"DDInter1018",
"DDInter1632"
] | Lactulose | Salbutamol | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Moderate | 1 | [
[
[
355,
24,
688
]
],
[
[
355,
21,
29209
],
[
29209,
60,
688
]
],
[
[
355,
24,
1220
],
[
1220,
62,
688
]
],
[
[
355,
24,
870
],
[
870,
... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Lactulose",
"{u} (Compound) causes {v} (Side Effect)",
"Anorexia"
],
[
"Anorexia",
"{u} (Side Effect) is caused b... | Lactulose (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Salbutamol (Compound)
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Salbuta... |
DB09122 | DB11986 | 1,613 | 484 | [
"DDInter1409",
"DDInter648"
] | Peginterferon beta-1a | Entrectinib | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
1613,
24,
484
]
],
[
[
1613,
63,
1247
],
[
1247,
23,
484
]
],
[
[
1613,
24,
1662
],
[
1662,
24,
484
]
],
[
[
1613,
63,
998
],
[
998,
... | [
[
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulf... | Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when... |
DB00945 | DB09293 | 1,479 | 116 | [
"DDInter20",
"DDInter954"
] | Acetylsalicylic acid | Iodide I-131 | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation do... | Moderate | 1 | [
[
[
1479,
24,
116
]
],
[
[
1479,
24,
1486
],
[
1486,
24,
116
]
],
[
[
1479,
63,
167
],
[
167,
24,
116
]
],
[
[
1479,
25,
365
],
[
365,
... | [
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methy... | Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases... |
DB01105 | DB12500 | 222 | 283 | [
"DDInter1665",
"DDInter714"
] | Sibutramine | Fedratinib | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
222,
24,
283
]
],
[
[
222,
23,
351
],
[
351,
23,
283
]
],
[
[
222,
62,
122
],
[
122,
23,
283
]
],
[
[
222,
23,
1339
],
[
1339,
6... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ribociclib"
],
[
... | Sibutramine may cause a minor interaction that can limit clinical effects when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Sibutramine may cause a minor interaction that can limit clinical effects when taken with Verapamil and Verapamil m... |
DB00470 | DB06282 | 530 | 516 | [
"DDInter601",
"DDInter1053"
] | Dronabinol | Levocetirizine | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
530,
24,
516
]
],
[
[
530,
63,
701
],
[
701,
24,
516
]
],
[
[
530,
24,
614
],
[
614,
24,
516
]
],
[
[
530,
1,
1614
],
[
1614,
24... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Dexmedetomidine a... |
DB01229 | DB12267 | 973 | 1,476 | [
"DDInter1377",
"DDInter233"
] | Paclitaxel | Brigatinib | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
973,
24,
1476
]
],
[
[
973,
24,
1206
],
[
1206,
23,
1476
]
],
[
[
973,
63,
168
],
[
168,
23,
1476
]
],
[
[
973,
63,
629
],
[
629,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemfibrozil"
],
[
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Gemfibrozil and Gemfibrozil may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortez... |
DB00694 | DB01259 | 51 | 392 | [
"DDInter485",
"DDInter1024"
] | Daunorubicin | Lapatinib | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
51,
24,
392
]
],
[
[
51,
6,
4973
],
[
4973,
45,
392
]
],
[
[
51,
18,
18008
],
[
18008,
46,
392
]
],
[
[
51,
7,
11074
],
[
11074,
... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Daunorubicin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)"... | Daunorubicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Daunorubicin (Compound) downregulates BAMBI (Gene) and BAMBI (Gene) is upregulated by Lapatinib (Compound)
Daunorubicin (Compound) upregulates HERC6 (Gene) and HERC6 (Gene) is upregulated by Lapatinib (Compound)
Daunorubicin (C... |
DB06674 | DB08904 | 908 | 375 | [
"DDInter837",
"DDInter342"
] | Golimumab | Certolizumab pegol | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Major | 2 | [
[
[
908,
25,
375
]
],
[
[
908,
62,
1461
],
[
1461,
23,
375
]
],
[
[
908,
23,
1193
],
[
1193,
62,
375
]
],
[
[
908,
63,
231
],
[
231,
... | [
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Golimumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin... | Golimumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Golimumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc... |
DB00400 | DB05676 | 353 | 1,513 | [
"DDInter843",
"DDInter111"
] | Griseofulvin | Apremilast | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. In July... | Moderate | 1 | [
[
[
353,
24,
1513
]
],
[
[
353,
24,
307
],
[
307,
23,
1513
]
],
[
[
353,
24,
1155
],
[
1155,
63,
1513
]
],
[
[
353,
62,
1101
],
[
1101,
... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apremilast"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[... | Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Apremilast
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib and Tucatin... |
DB04908 | DB06176 | 1,671 | 1,342 | [
"DDInter741",
"DDInter1616"
] | Flibanserin | Romidepsin | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
1671,
24,
1342
]
],
[
[
1671,
63,
820
],
[
820,
24,
1342
]
],
[
[
1671,
24,
1478
],
[
1478,
63,
1342
]
],
[
[
1671,
64,
600
],
[
600,
... | [
[
[
"Flibanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Flibanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[... | Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Iva... |
DB00013 | DB00569 | 1,255 | 553 | [
"DDInter1905",
"DDInter775"
] | Urokinase | Fondaparinux | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in he... | Major | 2 | [
[
[
1255,
25,
553
]
],
[
[
1255,
23,
539
],
[
539,
62,
553
]
],
[
[
1255,
24,
972
],
[
972,
63,
553
]
],
[
[
1255,
24,
109
],
[
109,
... | [
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fondaparinux"
]
],
[
[
"Urokinase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
... | Urokinase may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Fondaparinux
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate and Cholin... |
DB00635 | DB01021 | 1,573 | 674 | [
"DDInter1515",
"DDInter1861"
] | Prednisone | Trichlormethiazide | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830) | Moderate | 1 | [
[
[
1573,
24,
674
]
],
[
[
1573,
63,
1014
],
[
1014,
40,
674
]
],
[
[
1573,
24,
178
],
[
178,
1,
674
]
],
[
[
1573,
24,
359
],
[
359,
... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiazide"
]... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resembles Trichlormethiazide (Compound)
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide and Polythiazide (Compound) resembles Trichl... |
DB00375 | DB00451 | 1,037 | 542 | [
"DDInter433",
"DDInter1064"
] | Colestipol | Levothyroxine | Bile acid sequestrants like colestipol have been in use since the 1970s.[FDA Label, F4555, F4567, L6262] And even though such an agent may very well be useful in reducing elevated cholesterol levels and decreasing the risk for atherosclerotic vascular disease due to hypercholesterolemia, colestipol is still generally o... | Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quant... | Moderate | 1 | [
[
[
1037,
24,
542
]
],
[
[
1037,
63,
1152
],
[
1152,
1,
542
]
],
[
[
1037,
21,
28957
],
[
28957,
60,
542
]
],
[
[
1037,
24,
467
],
[
467,
... | [
[
[
"Colestipol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levothyroxine"
]
],
[
[
"Colestipol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
... | Colestipol may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine (Compound) resembles Levothyroxine (Compound)
Colestipol (Compound) causes Arthralgia (Side Effect) and Arthralgia (Side Effect) is caused by Levothyroxine (Compound)
Colestipol may cause a moderate ... |
DB00393 | DB01041 | 854 | 770 | [
"DDInter1295",
"DDInter1789"
] | Nimodipine | Thalidomide | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction ... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
854,
24,
770
]
],
[
[
854,
6,
7524
],
[
7524,
45,
770
]
],
[
[
854,
21,
28768
],
[
28768,
60,
770
]
],
[
[
854,
25,
609
],
[
609,
... | [
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Nimodipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)"... | Nimodipine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Thalidomide (Compound)
Nimodipine (Compound) causes Acne (Side Effect) and Acne (Side Effect) is caused by Thalidomide (Compound)
Nimodipine may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may caus... |
DB00197 | DB00831 | 1,324 | 1,178 | [
"DDInter1881",
"DDInter1866"
] | Troglitazone | Trifluoperazine | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Moderate | 1 | [
[
[
1324,
24,
1178
]
],
[
[
1324,
24,
695
],
[
695,
40,
1178
]
],
[
[
1324,
24,
1630
],
[
1630,
1,
1178
]
],
[
[
1324,
24,
417
],
[
417,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
],
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine (Compound) resembles Trifluoperazine (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Trifluopera... |
DB00635 | DB09043 | 1,573 | 135 | [
"DDInter1515",
"DDInter36"
] | Prednisone | Albiglutide | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
1573,
24,
135
]
],
[
[
1573,
24,
126
],
[
126,
23,
135
]
],
[
[
1573,
40,
1103
],
[
1103,
23,
135
]
],
[
[
1573,
63,
1252
],
[
1252,
... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Prednisone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit cli... |
DB00407 | DB08896 | 202 | 292 | [
"DDInter115",
"DDInter1576"
] | Ardeparin | Regorafenib | Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation of heparin extracted from porcine intestinal mucosa. Its molecular weight ranges from 2000 to 15,000 with... | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Major | 2 | [
[
[
202,
25,
292
]
],
[
[
202,
21,
28890
],
[
28890,
60,
292
]
],
[
[
202,
63,
1560
],
[
1560,
24,
292
]
],
[
[
202,
24,
121
],
[
121,
... | [
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Regorafenib"
]
],
[
[
"Ardeparin",
"{u} (Compound) causes {v} (Side Effect)",
"Myocardial infarction"
],
[
"Myocardial infarction",
"{u} (Side Effect)... | Ardeparin (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Regorafenib (Compound)
Ardeparin may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate disea... |
DB06699 | DB11718 | 774 | 927 | [
"DDInter493",
"DDInter640"
] | Degarelix | Encorafenib | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
774,
24,
927
]
],
[
[
774,
62,
112
],
[
112,
23,
927
]
],
[
[
774,
24,
720
],
[
720,
24,
927
]
],
[
[
774,
63,
216
],
[
216,
24,... | [
[
[
"Degarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Degarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Degarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Mine... |
DB00193 | DB08871 | 534 | 36 | [
"DDInter1841",
"DDInter666"
] | Tramadol | Eribulin | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
534,
24,
36
]
],
[
[
534,
24,
1424
],
[
1424,
24,
36
]
],
[
[
534,
25,
820
],
[
820,
24,
36
]
],
[
[
534,
64,
268
],
[
268,
24,
... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Quin... | Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Tramadol may lead to a major life threatening interaction when taken with Alimemazine and Alimemazine may cause a moderate... |
DB01577 | DB06723 | 1,529 | 115 | [
"DDInter1161",
"DDInter58"
] | Metamfetamine | Aluminum hydroxide | Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potentia... | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Moderate | 1 | [
[
[
1529,
24,
115
]
],
[
[
1529,
63,
401
],
[
401,
23,
115
]
],
[
[
1529,
40,
93
],
[
93,
24,
115
]
],
[
[
1529,
24,
478
],
[
478,
2... | [
[
[
"Metamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Metamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"... | Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Metamfetamine (Compound) resembles Dextroamphetamine (Compound) and Dextroamphetamine may cause a m... |
DB01225 | DB01268 | 500 | 1,151 | [
"DDInter645",
"DDInter1731"
] | Enoxaparin | Sunitinib | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
500,
24,
1151
]
],
[
[
500,
21,
28642
],
[
28642,
60,
1151
]
],
[
[
500,
63,
758
],
[
758,
24,
1151
]
],
[
[
500,
25,
235
],
[
235,
... | [
[
[
"Enoxaparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Enoxaparin",
"{u} (Compound) causes {v} (Side Effect)",
"Shock"
],
[
"Shock",
"{u} (Side Effect) is caused by {v}... | Enoxaparin (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Sunitinib (Compound)
Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Enoxap... |
DB00656 | DB00675 | 827 | 888 | [
"DDInter1851",
"DDInter1744"
] | Trazodone | Tamoxifen | Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and se... | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Moderate | 1 | [
[
[
827,
24,
888
]
],
[
[
827,
24,
832
],
[
832,
40,
888
]
],
[
[
827,
63,
1594
],
[
1594,
40,
888
]
],
[
[
827,
24,
543
],
[
543,
6... | [
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
]
],
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
[
... | Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine (Compound) resembles Tamoxifen (Compound)
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Tamoxifen (Compou... |
DB00620 | DB01089 | 175 | 1,340 | [
"DDInter1855",
"DDInter502"
] | Triamcinolone | Deserpidine | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Deserpidine is an ester alkaloid drug isolated from Rauwolfia canescens (family Apocynaceae) with antipsychotic and antihypertensive properties that has been used for the control of high blood pressure and for the relief of psychotic behavior. | Moderate | 1 | [
[
[
175,
24,
1340
]
],
[
[
175,
63,
1245
],
[
1245,
40,
1340
]
],
[
[
175,
24,
1411
],
[
1411,
63,
1340
]
],
[
[
175,
40,
891
],
[
891,
... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deserpidine"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Reserpine"
],
... | Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Reserpine and Reserpine (Compound) resembles Deserpidine (Compound)
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction tha... |
DB00649 | DB08865 | 231 | 1,593 | [
"DDInter1710",
"DDInter448"
] | Stavudine | Crizotinib | A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
231,
24,
1593
]
],
[
[
231,
18,
5660
],
[
5660,
46,
1593
]
],
[
[
231,
7,
3727
],
[
3727,
46,
1593
]
],
[
[
231,
18,
8914
],
[
8914,
... | [
[
[
"Stavudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Stavudine",
"{u} (Compound) downregulates {v} (Gene)",
"TNIP1"
],
[
"TNIP1",
"{u} (Gene) is upregulated by {v} (C... | Stavudine (Compound) downregulates TNIP1 (Gene) and TNIP1 (Gene) is upregulated by Crizotinib (Compound)
Stavudine (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Crizotinib (Compound)
Stavudine (Compound) downregulates NUP85 (Gene) and NUP85 (Gene) is downregulated by Crizotinib (Compound)
Stavudine... |
DB00067 | DB00526 | 317 | 1,555 | [
"DDInter1921",
"DDInter1355"
] | Vasopressin | Oxaliplatin | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third an... | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Moderate | 1 | [
[
[
317,
24,
1555
]
],
[
[
317,
24,
79
],
[
79,
24,
1555
]
],
[
[
317,
24,
1213
],
[
1213,
63,
1555
]
],
[
[
317,
63,
521
],
[
521,
... | [
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
... | Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasati... |
DB00443 | DB01309 | 251 | 1,254 | [
"DDInter195",
"DDInter933"
] | Betamethasone | Insulin glulisine | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Moderate | 1 | [
[
[
251,
24,
1254
]
],
[
[
251,
40,
1103
],
[
1103,
23,
1254
]
],
[
[
251,
40,
167
],
[
167,
24,
1254
]
],
[
[
251,
24,
1603
],
[
1603,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may ca... | Betamethasone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Insulin glulisine
Betamethasone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when tak... |
DB00328 | DB08870 | 831 | 850 | [
"DDInter921",
"DDInter228"
] | Indomethacin | Brentuximab vedotin | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlor... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
831,
24,
850
]
],
[
[
831,
24,
267
],
[
267,
24,
850
]
],
[
[
831,
24,
1033
],
[
1033,
63,
850
]
],
[
[
831,
63,
245
],
[
245,
2... | [
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
... | Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisi... |
DB00994 | DB09473 | 361 | 884 | [
"DDInter1277",
"DDInter918"
] | Neomycin | Indium In-111 oxyquinoline | Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of _Streptomyces fradiae_. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as [framycetin], is the most active component of the complex and neomycin C is the isomer o... | Indium In 111 oxyquinoline (oxine) is a diagnostic radiopharmaceutical intended for radiolabeling of autologous leukocytes. It is composed of a 3:1 saturated complex of In-111 isotope and oxyquinoline. Indium-111 decays by isomeric transition and electron capture to cadmium-111, emitting a gamma ray that can be detecte... | Moderate | 1 | [
[
[
361,
24,
884
]
],
[
[
361,
24,
1448
],
[
1448,
24,
884
]
],
[
[
361,
63,
50
],
[
50,
24,
884
]
],
[
[
361,
64,
1441
],
[
1441,
2... | [
[
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indium In-111 oxyquinoline"
]
],
[
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
... | Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Indium In-111 oxyquinoline
Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Sulfa... |
DB00294 | DB11979 | 1,336 | 1,320 | [
"DDInter701",
"DDInter625"
] | Etonogestrel | Elagolix | Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001. | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
1336,
24,
1320
]
],
[
[
1336,
24,
129
],
[
129,
24,
1320
]
],
[
[
1336,
24,
484
],
[
484,
63,
1320
]
],
[
[
1336,
40,
35
],
[
35,
... | [
[
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
... | Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and... |
DB00673 | DB09098 | 723 | 98 | [
"DDInter112",
"DDInter1700"
] | Aprepitant | Somatrem | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
723,
24,
98
]
],
[
[
723,
63,
608
],
[
608,
23,
98
]
],
[
[
723,
23,
1459
],
[
1459,
23,
98
]
],
[
[
723,
24,
671
],
[
671,
24,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somatrem
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Dolutegravir and Dolutegravir... |
DB00902 | DB00988 | 104 | 817 | [
"DDInter1168",
"DDInter584"
] | Methdilazine | Dopamine | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | One of the catecholamine neurotransmitters in the brain. It is derived from tyrosine and is the precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (receptors, dopamine) mediate its action. | Moderate | 1 | [
[
[
104,
24,
817
]
],
[
[
104,
24,
584
],
[
584,
1,
817
]
],
[
[
104,
63,
874
],
[
874,
40,
817
]
],
[
[
104,
25,
1311
],
[
1311,
62... | [
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dopamine"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levonordefrin"
],
... | Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Levonordefrin and Levonordefrin (Compound) resembles Dopamine (Compound)
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine (Compound) resembles Dopamine (Co... |
DB00398 | DB00762 | 79 | 613 | [
"DDInter1702",
"DDInter973"
] | Sorafenib | Irinotecan | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Moderate | 1 | [
[
[
79,
24,
613
]
],
[
[
79,
24,
869
],
[
869,
63,
613
]
],
[
[
79,
6,
8374
],
[
8374,
45,
613
]
],
[
[
79,
7,
4450
],
[
4450,
46,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Irinotecan"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
... | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan
Sorafenib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Irinotecan (Compound)
Sorafenib (Compound) u... |
DB00635 | DB11952 | 1,573 | 800 | [
"DDInter1515",
"DDInter612"
] | Prednisone | Duvelisib | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Moderate | 1 | [
[
[
1573,
24,
800
]
],
[
[
1573,
63,
663
],
[
663,
24,
800
]
],
[
[
1573,
24,
270
],
[
270,
63,
800
]
],
[
[
1573,
24,
1683
],
[
1683,
... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Oc... |
DB00557 | DB01211 | 252 | 609 | [
"DDInter895",
"DDInter393"
] | Hydroxyzine | Clarithromycin | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
252,
24,
609
]
],
[
[
252,
21,
28662
],
[
28662,
60,
609
]
],
[
[
252,
63,
600
],
[
600,
23,
609
]
],
[
[
252,
24,
222
],
[
222,
... | [
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Hydroxyzine",
"{u} (Compound) causes {v} (Side Effect)",
"Tremor"
],
[
"Tremor",
"{u} (Side Effect) is caus... | Hydroxyzine (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Clarithromycin (Compound)
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Clarith... |
DB00334 | DB01105 | 867 | 222 | [
"DDInter1326",
"DDInter1665"
] | Olanzapine | Sibutramine | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug inte... | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
867,
24,
222
]
],
[
[
867,
6,
8374
],
[
8374,
45,
222
]
],
[
[
867,
63,
600
],
[
600,
23,
222
]
],
[
[
867,
24,
609
],
[
609,
62... | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Olanzapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Olanzapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound)
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Olanzapine may c... |
DB00393 | DB12010 | 854 | 214 | [
"DDInter1295",
"DDInter785"
] | Nimodipine | Fostamatinib | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction ... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
854,
24,
214
]
],
[
[
854,
1,
1428
],
[
1428,
24,
214
]
],
[
[
854,
24,
723
],
[
723,
24,
214
]
],
[
[
854,
63,
600
],
[
600,
24... | [
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Nimodipine",
"{u} (Compound) resembles {v} (Compound)",
"Isradipine"
],
[
"Isradipine",
"{u} may cause a moder... | Nimodipine (Compound) resembles Isradipine (Compound) and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that cou... |
DB01149 | DB09143 | 851 | 313 | [
"DDInter1274",
"DDInter1701"
] | Nefazodone | Sonidegib | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Major | 2 | [
[
[
851,
25,
313
]
],
[
[
851,
63,
1215
],
[
1215,
23,
313
]
],
[
[
851,
25,
478
],
[
478,
24,
313
]
],
[
[
851,
25,
484
],
[
484,
6... | [
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sonidegib"
]
],
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
],
[
"Lansopraz... | Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Sonidegib
Nefazodone may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a... |
DB01045 | DB01156 | 463 | 593 | [
"DDInter1590",
"DDInter252"
] | Rifampicin | Bupropion | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Moderate | 1 | [
[
[
463,
24,
593
]
],
[
[
463,
6,
3486
],
[
3486,
45,
593
]
],
[
[
463,
64,
126
],
[
126,
24,
593
]
],
[
[
463,
25,
1033
],
[
1033,
... | [
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Rifampicin",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
... | Rifampicin (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Bupropion (Compound)
Rifampicin may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Bupropion
Rifampicin may lead to a major life thr... |
DB00305 | DB00446 | 377 | 597 | [
"DDInter1232",
"DDInter351"
] | Mitomycin | Chloramphenicol | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of th... | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Moderate | 1 | [
[
[
377,
24,
597
]
],
[
[
377,
7,
5002
],
[
5002,
46,
597
]
],
[
[
377,
18,
6718
],
[
6718,
57,
597
]
],
[
[
377,
21,
28787
],
[
28787,
... | [
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
]
],
[
[
"Mitomycin",
"{u} (Compound) upregulates {v} (Gene)",
"SNAP25"
],
[
"SNAP25",
"{u} (Gene) is upregulated by {... | Mitomycin (Compound) upregulates SNAP25 (Gene) and SNAP25 (Gene) is upregulated by Chloramphenicol (Compound)
Mitomycin (Compound) downregulates USP22 (Gene) and USP22 (Gene) is downregulated by Chloramphenicol (Compound)
Mitomycin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Chl... |
DB06204 | DB06706 | 768 | 468 | [
"DDInter1746",
"DDInter985"
] | Tapentadol | Isometheptene | Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA... | Isometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches. | Moderate | 1 | [
[
[
768,
24,
468
]
],
[
[
768,
63,
480
],
[
480,
24,
468
]
],
[
[
768,
24,
144
],
[
144,
63,
468
]
],
[
[
768,
64,
222
],
[
222,
24,... | [
[
[
"Tapentadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
],
[
[
"Tapentadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[... | Tapentadol may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Tapentadol may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olo... |
DB05015 | DB08880 | 1,077 | 1,510 | [
"DDInter174",
"DDInter1771"
] | Belinostat | Teriflunomide | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
1077,
25,
1510
]
],
[
[
1077,
24,
129
],
[
129,
63,
1510
]
],
[
[
1077,
24,
1136
],
[
1136,
24,
1510
]
],
[
[
1077,
63,
563
],
[
563,
... | [
[
[
"Belinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzal... | Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and ... |
DB00350 | DB00477 | 1,214 | 216 | [
"DDInter1226",
"DDInter363"
] | Minoxidil | Chlorpromazine | A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Moderate | 1 | [
[
[
1214,
24,
216
]
],
[
[
1214,
24,
1178
],
[
1178,
1,
216
]
],
[
[
1214,
63,
902
],
[
902,
40,
216
]
],
[
[
1214,
24,
1216
],
[
1216,
... | [
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],
... | Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Chlorpromazine (Compound)
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Chlorpromazine... |
DB00261 | DB00315 | 702 | 767 | [
"DDInter93",
"DDInter1969"
] | Anagrelide | Zolmitriptan | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Zolmitriptan is a member of the triptan class of 5-hydroxytryptamine(5-HT)<sub>1B/1D/(1F)</sub> receptor agonists used to treat acute migraine.[A462, L12978] [Sumatriptan] was the first triptan to be developed, but had poor oral bioavailability and lipophilicity. This led to the development of second-generation triptan... | Moderate | 1 | [
[
[
702,
24,
767
]
],
[
[
702,
24,
43
],
[
43,
40,
767
]
],
[
[
702,
6,
7950
],
[
7950,
45,
767
]
],
[
[
702,
18,
10375
],
[
10375,
... | [
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zolmitriptan"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melatonin"
],
[
... | Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Melatonin and Melatonin (Compound) resembles Zolmitriptan (Compound)
Anagrelide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Zolmitriptan (Compound)
Anagrelide (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Ge... |
DB11837 | DB11915 | 1,297 | 1,293 | [
"DDInter1351",
"DDInter1909"
] | Osilodrostat | Valbenazine | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Moderate | 1 | [
[
[
1297,
24,
1293
]
],
[
[
1297,
62,
112
],
[
112,
23,
1293
]
],
[
[
1297,
63,
521
],
[
521,
24,
1293
]
],
[
[
1297,
24,
283
],
[
283,
... | [
[
[
"Osilodrostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Osilodrostat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Osilodrostat may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Valbenazine
Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and ... |
DB06718 | DB09122 | 1,687 | 1,613 | [
"DDInter1709",
"DDInter1409"
] | Stanozolol | Peginterferon beta-1a | Stanozolol is a synthetic anabolic steroid with therapeutic uses in treating hereditary angioedema. Stanozolol is derived from testosterone, and has been abused by several high profile professional athletes. | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
1687,
24,
1613
]
],
[
[
1687,
24,
1627
],
[
1627,
24,
1613
]
],
[
[
1687,
63,
267
],
[
267,
24,
1613
]
],
[
[
1687,
40,
155
],
[
155,
... | [
[
[
"Stanozolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Stanozolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
... | Stanozolol may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Stanozolol may cause a moderate interaction that could exacerbate diseases when taken with Naltrexo... |
DB00381 | DB01234 | 376 | 1,220 | [
"DDInter79",
"DDInter513"
] | Amlodipine | Dexamethasone | Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
376,
24,
1220
]
],
[
[
376,
24,
870
],
[
870,
1,
1220
]
],
[
[
376,
24,
175
],
[
175,
40,
1220
]
],
[
[
376,
6,
21998
],
[
21998,
... | [
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
... | Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Dex... |
DB00694 | DB15091 | 51 | 676 | [
"DDInter485",
"DDInter1901"
] | Daunorubicin | Upadacitinib | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
51,
25,
676
]
],
[
[
51,
63,
1461
],
[
1461,
23,
676
]
],
[
[
51,
24,
1430
],
[
1430,
24,
676
]
],
[
[
51,
25,
1593
],
[
1593,
2... | [
[
[
"Daunorubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitam... | Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Si... |
DB00108 | DB08870 | 1,066 | 850 | [
"DDInter1268",
"DDInter228"
] | Natalizumab | Brentuximab vedotin | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Major | 2 | [
[
[
1066,
25,
850
]
],
[
[
1066,
24,
496
],
[
496,
63,
850
]
],
[
[
1066,
25,
611
],
[
611,
24,
850
]
],
[
[
1066,
24,
267
],
[
267,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
],
... | Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Natalizumab may lead to a major life threatening interaction when taken with Dacarba... |
DB01105 | DB08901 | 222 | 1,468 | [
"DDInter1665",
"DDInter1492"
] | Sibutramine | Ponatinib | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
222,
24,
1468
]
],
[
[
222,
24,
478
],
[
478,
24,
1468
]
],
[
[
222,
6,
8374
],
[
8374,
45,
1468
]
],
[
[
222,
18,
2114
],
[
2114,
... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
... | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Sibutramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ponatinib (Compound)
Sibutramine (Compoun... |
DB00682 | DB01602 | 126 | 339 | [
"DDInter1951",
"DDInter159"
] | Warfarin | Bacampicillin | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Bacampicillin is a prodrug of ampicillin and is microbiologically inactive. It is absorbed following oral administration. During absorption from the gastrointestinal tract, bacampicillin is hydrolyzed by esterases present in the intestinal wall. It is microbiologically active as ampicillin, and exerts a bactericidal ac... | Moderate | 1 | [
[
[
126,
24,
339
]
],
[
[
126,
63,
703
],
[
703,
1,
339
]
],
[
[
126,
24,
950
],
[
950,
40,
339
]
],
[
[
126,
64,
916
],
[
916,
40,
... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bacampicillin"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbenicillin"
],
[
... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Carbenicillin and Carbenicillin (Compound) resembles Bacampicillin (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cloxacillin and Cloxacillin (Compound) resembles Bacampicillin (... |
DB00976 | DB09143 | 1,056 | 313 | [
"DDInter1758",
"DDInter1701"
] | Telithromycin | Sonidegib | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Major | 2 | [
[
[
1056,
25,
313
]
],
[
[
1056,
63,
1559
],
[
1559,
23,
313
]
],
[
[
1056,
24,
379
],
[
379,
23,
313
]
],
[
[
1056,
25,
478
],
[
478,
... | [
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sonidegib"
]
],
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famot... | Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a minor interaction that can limit clinical effects when taken with Sonidegib
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole and Ra... |
DB00574 | DB00889 | 121 | 1,133 | [
"DDInter717",
"DDInter840"
] | Fenfluramine | Granisetron | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Major | 2 | [
[
[
121,
25,
1133
]
],
[
[
121,
24,
1213
],
[
1213,
63,
1133
]
],
[
[
121,
25,
633
],
[
633,
63,
1133
]
],
[
[
121,
25,
888
],
[
888,
... | [
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Granisetron"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
"Dasati... | Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Granisetron
Fenfluramine may lead to a major life threatening interaction when taken with Lisdexamfetamine and Lisdexamfeta... |
DB05812 | DB12457 | 1,374 | 1,180 | [
"DDInter8",
"DDInter1598"
] | Abiraterone | Rimegepant | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several p... | Moderate | 1 | [
[
[
1374,
24,
1180
]
],
[
[
1374,
24,
1619
],
[
1619,
24,
1180
]
],
[
[
1374,
25,
351
],
[
351,
24,
1180
]
],
[
[
1374,
24,
283
],
[
283,
... | [
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rimegepant"
]
],
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
... | Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Abiraterone may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause ... |
DB00704 | DB08865 | 267 | 1,593 | [
"DDInter1263",
"DDInter448"
] | Naltrexone | Crizotinib | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
267,
24,
1593
]
],
[
[
267,
6,
4973
],
[
4973,
45,
1593
]
],
[
[
267,
7,
2900
],
[
2900,
46,
1593
]
],
[
[
267,
18,
8386
],
[
8386,
... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Naltrexone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Naltrexone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Crizotinib (Compound)
Naltrexone (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Crizotinib (Compound)
Naltrexone (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Crizotinib (Compound)
Naltrexone (... |
DB01234 | DB11837 | 1,220 | 1,297 | [
"DDInter513",
"DDInter1351"
] | Dexamethasone | Osilodrostat | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
1220,
24,
1297
]
],
[
[
1220,
24,
1135
],
[
1135,
23,
1297
]
],
[
[
1220,
25,
466
],
[
466,
62,
1297
]
],
[
[
1220,
23,
271
],
[
271,
... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
... | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Dexamethasone may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide ma... |
DB00443 | DB08868 | 251 | 1,011 | [
"DDInter195",
"DDInter737"
] | Betamethasone | Fingolimod | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
251,
25,
1011
]
],
[
[
251,
5,
11594
],
[
11594,
44,
1011
]
],
[
[
251,
18,
9199
],
[
9199,
45,
1011
]
],
[
[
251,
6,
8374
],
[
8374,
... | [
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Betamethasone",
"{u} (Compound) treats {v} (Disease)",
"multiple sclerosis"
],
[
"multiple sclerosis",
"{u} (Disease) is tre... | Betamethasone (Compound) treats multiple sclerosis (Disease) and multiple sclerosis (Disease) is treated by Fingolimod (Compound)
Betamethasone (Compound) downregulates SPHK1 (Gene) and SPHK1 (Gene) is bound by Fingolimod (Compound)
Betamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fingolimod (... |
DB00884 | DB08938 | 1,008 | 1,384 | [
"DDInter1604",
"DDInter1112"
] | Risedronic acid | Magaldrate | Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label]. | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Moderate | 1 | [
[
[
1008,
24,
1384
]
],
[
[
1008,
24,
428
],
[
428,
63,
1384
]
],
[
[
1008,
24,
1596
],
[
1596,
24,
1384
]
],
[
[
1008,
40,
1485
],
[
1485... | [
[
[
"Risedronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Risedronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"... | Risedronic acid may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate
Risedronic acid may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00307 | DB00685 | 1,101 | 1,299 | [
"DDInter202",
"DDInter1887"
] | Bexarotene | Trovafloxacin | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Major | 2 | [
[
[
1101,
25,
1299
]
],
[
[
1101,
21,
29093
],
[
29093,
60,
1299
]
],
[
[
1101,
24,
896
],
[
896,
62,
1299
]
],
[
[
1101,
24,
322
],
[
322... | [
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trovafloxacin"
]
],
[
[
"Bexarotene",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) is caused by {v} (Compo... | Bexarotene (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Trovafloxacin (Compound)
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a minor interaction that can limit clinical effects when taken with Trovafloxaci... |
DB00092 | DB00641 | 58 | 467 | [
"DDInter40",
"DDInter1675"
] | Alefacept | Simvastatin | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Moderate | 1 | [
[
[
58,
24,
467
]
],
[
[
58,
24,
1428
],
[
1428,
23,
467
]
],
[
[
58,
24,
126
],
[
126,
62,
467
]
],
[
[
58,
24,
800
],
[
800,
63,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isradipine"
],
[
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine may cause a minor interaction that can limit clinical effects when taken with Simvastatin
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin ma... |
DB00445 | DB06186 | 322 | 1,439 | [
"DDInter655",
"DDInter969"
] | Epirubicin | Ipilimumab | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approva... | Moderate | 1 | [
[
[
322,
24,
1439
]
],
[
[
322,
63,
912
],
[
912,
24,
1439
]
],
[
[
322,
24,
1412
],
[
1412,
63,
1439
]
],
[
[
322,
24,
267
],
[
267,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Calas... |
DB00515 | DB00959 | 589 | 1,486 | [
"DDInter387",
"DDInter1191"
] | Cisplatin | Methylprednisolone | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Moderate | 1 | [
[
[
589,
24,
1486
]
],
[
[
589,
24,
175
],
[
175,
40,
1486
]
],
[
[
589,
24,
167
],
[
167,
1,
1486
]
],
[
[
589,
63,
251
],
[
251,
1... | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],... | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Me... |
DB01006 | DB15093 | 300 | 1,654 | [
"DDInter1040",
"DDInter1698"
] | Letrozole | Somapacitan | Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
300,
24,
1654
]
],
[
[
300,
24,
351
],
[
351,
24,
1654
]
],
[
[
300,
63,
723
],
[
723,
24,
1654
]
],
[
[
300,
63,
1101
],
[
1101,
... | [
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
... | Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepit... |
DB00852 | DB00912 | 1,445 | 473 | [
"DDInter1545",
"DDInter1581"
] | Pseudoephedrine | Repaglinide | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseud... | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
1445,
24,
473
]
],
[
[
1445,
21,
28763
],
[
28763,
60,
473
]
],
[
[
1445,
64,
551
],
[
551,
24,
473
]
],
[
[
1445,
63,
73
],
[
73,
... | [
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Pseudoephedrine",
"{u} (Compound) causes {v} (Side Effect)",
"Chest pain"
],
[
"Chest pain",
"{u} (Side Ef... | Pseudoephedrine (Compound) causes Chest pain (Side Effect) and Chest pain (Side Effect) is caused by Repaglinide (Compound)
Pseudoephedrine may lead to a major life threatening interaction when taken with Phenelzine and Phenelzine may cause a moderate interaction that could exacerbate diseases when taken with Repaglini... |
DB00285 | DB00569 | 1,100 | 553 | [
"DDInter1927",
"DDInter775"
] | Venlafaxine | Fondaparinux | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in he... | Moderate | 1 | [
[
[
1100,
24,
553
]
],
[
[
1100,
21,
28681
],
[
28681,
60,
553
]
],
[
[
1100,
25,
222
],
[
222,
63,
553
]
],
[
[
1100,
1,
643
],
[
643,
... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fondaparinux"
]
],
[
[
"Venlafaxine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Si... | Venlafaxine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Fondaparinux (Compound)
Venlafaxine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Fo... |
DB10315 | DB11581 | 1,137 | 1,456 | [
"DDInter1127",
"DDInter1926"
] | Measles virus vaccine live attenuated | Venetoclax | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Major | 2 | [
[
[
1137,
25,
1456
]
],
[
[
1137,
64,
259
],
[
259,
24,
1456
]
],
[
[
1137,
25,
1476
],
[
1476,
63,
1456
]
],
[
[
1137,
25,
1093
],
[
1093... | [
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ril... | Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken wi... |
DB01575 | DB06777 | 1,054 | 780 | [
"DDInter1005",
"DDInter348"
] | Kaolin | Chenodeoxycholic acid | Kaolin is a layered silicate mineral. Kaolin is used in ceramics, medicine, coated paper, as a food additive, in toothpaste, as a light diffusing material in white incandescent light bulbs, and in cosmetics. Until the early 1990s it was the active substance of anti-diarrhoea medicine Kaopectate. | Chenodeoxycholic acid (or Chenodiol) is an epimer of ursodeoxycholic acid (DB01586). Chenodeoxycholic acid is a bile acid naturally found in the body. It works by dissolving the cholesterol that makes gallstones and inhibiting production of cholesterol in the liver and absorption in the intestines, which helps to decre... | Moderate | 1 | [
[
[
1054,
24,
780
]
],
[
[
1054,
62,
17
],
[
17,
21,
28719
],
[
28719,
60,
780
]
],
[
[
1054,
62,
772
],
[
772,
6,
8374
],
[
8374,
45,
... | [
[
[
"Kaolin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chenodeoxycholic acid"
]
],
[
[
"Kaolin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sotalol"
],
[
... | Kaolin may cause a minor interaction that can limit clinical effects when taken with Sotalol and Sotalol (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Chenodeoxycholic acid (Compound)
Kaolin may cause a minor interaction that can limit clinical effects when taken with Carvedilol and Carvedilo... |
DB00582 | DB01259 | 1,622 | 392 | [
"DDInter1946",
"DDInter1024"
] | Voriconazole | Lapatinib | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Major | 2 | [
[
[
1622,
25,
392
]
],
[
[
1622,
6,
8374
],
[
8374,
45,
392
]
],
[
[
1622,
21,
29429
],
[
29429,
60,
392
]
],
[
[
1622,
25,
1135
],
[
1135... | [
[
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
]
],
[
[
"Voriconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Lapa... | Voriconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lapatinib (Compound)
Voriconazole (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Lapatinib (Compound)
Voriconazole may lead to a major life threatening interaction when taken with Naloxegol and Nalo... |
DB00816 | DB06655 | 1,674 | 5 | [
"DDInter1346",
"DDInter1077"
] | Orciprenaline | Liraglutide | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
1674,
24,
5
]
],
[
[
1674,
62,
870
],
[
870,
24,
5
]
],
[
[
1674,
63,
245
],
[
245,
24,
5
]
],
[
[
1674,
24,
1630
],
[
1630,
24,... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Orciprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fludrocortisone"
]... | Orciprenaline may cause a minor interaction that can limit clinical effects when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Glimep... |
DB00939 | DB01240 | 1,338 | 885 | [
"DDInter1135",
"DDInter657"
] | Meclofenamic acid | Epoprostenol | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
1338,
24,
885
]
],
[
[
1338,
63,
1061
],
[
1061,
1,
885
]
],
[
[
1338,
21,
28714
],
[
28714,
60,
885
]
],
[
[
1338,
74,
1512
],
[
1512... | [
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostini... | Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Meclofenamic acid (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Epoprostenol (Compound)
Meclofenamic acid (Compo... |
DB00549 | DB12240 | 522 | 110 | [
"DDInter1955",
"DDInter1485"
] | Zafirlukast | Polatuzumab vedotin | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable link... | Moderate | 1 | [
[
[
522,
24,
110
]
],
[
[
522,
24,
129
],
[
129,
23,
110
]
],
[
[
522,
24,
467
],
[
467,
24,
110
]
],
[
[
522,
63,
268
],
[
268,
24,... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
... | Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Polatuzumab vedotin
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Simvasta... |
DB00899 | DB11130 | 411 | 407 | [
"DDInter1579",
"DDInter1344"
] | Remifentanil | Opium | Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depress... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
411,
24,
407
]
],
[
[
411,
63,
662
],
[
662,
24,
407
]
],
[
[
411,
40,
1454
],
[
1454,
24,
407
]
],
[
[
411,
1,
1322
],
[
1322,
... | [
[
[
"Remifentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Remifentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
... | Remifentanil may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Remifentanil (Compound) resembles Sufentanil (Compound) and Sufentanil may cause a moderate interaction that ... |
DB09098 | DB12015 | 98 | 1,033 | [
"DDInter1700",
"DDInter53"
] | Somatrem | Alpelisib | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate. Such discussion revolves around whether patients' natural dispo... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
98,
24,
1033
]
],
[
[
98,
63,
1135
],
[
1135,
23,
1033
]
],
[
[
98,
63,
1254
],
[
1254,
24,
1033
]
],
[
[
98,
23,
1612
],
[
1612,
... | [
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
"N... | Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Alpelisib
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin ... |
DB00388 | DB01067 | 1,636 | 959 | [
"DDInter1453",
"DDInter826"
] | Phenylephrine | Glipizide | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
1636,
24,
959
]
],
[
[
1636,
63,
245
],
[
245,
40,
959
]
],
[
[
1636,
24,
1411
],
[
1411,
1,
959
]
],
[
[
1636,
21,
28703
],
[
28703,
... | [
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
... | Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Co... |
DB00501 | DB00604 | 752 | 1,425 | [
"DDInter380",
"DDInter385"
] | Cimetidine | Cisapride | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Major | 2 | [
[
[
752,
25,
1425
]
],
[
[
752,
63,
883
],
[
883,
1,
1425
]
],
[
[
752,
6,
21998
],
[
21998,
45,
1425
]
],
[
[
752,
23,
112
],
[
112,
... | [
[
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
... | Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Cisapride (Compound)
Cimetidine (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Cisapride (Compound)
Cimetidine may cause a minor interaction that can li... |
DB00524 | DB01285 | 811 | 708 | [
"DDInter1199",
"DDInter445"
] | Metolazone | Corticotropin | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
811,
24,
708
]
],
[
[
811,
24,
455
],
[
455,
23,
708
]
],
[
[
811,
24,
659
],
[
659,
62,
708
]
],
[
[
811,
63,
245
],
[
245,
24,... | [
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[... | Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Corticotropin
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilan... |
DB00673 | DB00865 | 723 | 939 | [
"DDInter112",
"DDInter187"
] | Aprepitant | Benzphetamine | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) | Moderate | 1 | [
[
[
723,
24,
939
]
],
[
[
723,
25,
704
],
[
704,
1,
939
]
],
[
[
723,
23,
307
],
[
307,
1,
939
]
],
[
[
723,
63,
576
],
[
576,
1,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzphetamine"
]
],
[
[
"Aprepitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fentanyl"
],
[
"Fentanyl"... | Aprepitant may lead to a major life threatening interaction when taken with Fentanyl and Fentanyl (Compound) resembles Benzphetamine (Compound)
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (Compound) resembles Benzphetamine (Compound)
Aprepitant may ca... |
DB00245 | DB00341 | 357 | 1,242 | [
"DDInter181",
"DDInter343"
] | Benzatropine | Cetirizine | Benztropine, with the chemical formula 3alpha-diphenylmethoxytropane, is a tropane-based dopamine inhibitor used for the symptomatic treatment of Parkinson's disease. It is a combination molecule between a tropane ring, similar to cocaine, and a diphenyl ether from the dialkylpiperazines determined to be a dopamine upt... | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms , . One of the most common uses for this drug is for a condition called _alle... | Moderate | 1 | [
[
[
357,
24,
1242
]
],
[
[
357,
40,
465
],
[
465,
1,
1242
]
],
[
[
357,
35,
537
],
[
537,
63,
1242
]
],
[
[
357,
24,
543
],
[
543,
6... | [
[
[
"Benzatropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
]
],
[
[
"Benzatropine",
"{u} (Compound) resembles {v} (Compound)",
"Chlorcyclizine"
],
[
"Chlorcyclizine",
"{u} (Compou... | Benzatropine (Compound) resembles Chlorcyclizine (Compound) and Chlorcyclizine (Compound) resembles Cetirizine (Compound)
Benzatropine (Compound) resembles Cyclizine (Compound) and Benzatropine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate i... |
DB00305 | DB00851 | 377 | 611 | [
"DDInter1232",
"DDInter463"
] | Mitomycin | Dacarbazine | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of th... | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | Moderate | 1 | [
[
[
377,
24,
611
]
],
[
[
377,
7,
7153
],
[
7153,
46,
611
]
],
[
[
377,
54,
19138
],
[
19138,
15,
611
]
],
[
[
377,
18,
9650
],
[
9650,
... | [
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacarbazine"
]
],
[
[
"Mitomycin",
"{u} (Compound) upregulates {v} (Gene)",
"PCK2"
],
[
"PCK2",
"{u} (Gene) is upregulated by {v} (Comp... | Mitomycin (Compound) upregulates PCK2 (Gene) and PCK2 (Gene) is upregulated by Dacarbazine (Compound)
Mitomycin (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Dacarbazine (Compound)
Mitomycin (Compound) downregulates HMGCS1 (Gene) and HMGCS1 (G... |
DB00501 | DB00554 | 752 | 1,027 | [
"DDInter380",
"DDInter1478"
] | Cimetidine | Piroxicam | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. | Minor | 0 | [
[
[
752,
23,
1027
]
],
[
[
752,
6,
16560
],
[
16560,
45,
1027
]
],
[
[
752,
24,
959
],
[
959,
63,
1027
]
],
[
[
752,
23,
222
],
[
222,
... | [
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Piroxicam"
]
],
[
[
"Cimetidine",
"{u} (Compound) binds {v} (Gene)",
"SLC22A8"
],
[
"SLC22A8",
"{u} (Gene) is bound by {v} (Compound)",
... | Cimetidine (Compound) binds SLC22A8 (Gene) and SLC22A8 (Gene) is bound by Piroxicam (Compound)
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam
Cimetidine may cause... |
DB01035 | DB11988 | 1,401 | 270 | [
"DDInter1524",
"DDInter1321"
] | Procainamide | Ocrelizumab | A derivative of procaine with less CNS action. | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
1401,
24,
270
]
],
[
[
1401,
25,
1491
],
[
1491,
24,
270
]
],
[
[
1401,
64,
485
],
[
485,
24,
270
]
],
[
[
1401,
24,
259
],
[
259,
... | [
[
[
"Procainamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
],
[
"Mido... | Procainamide may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Procainamide may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may cause a mode... |
DB04865 | DB11627 | 4 | 1,367 | [
"DDInter1335",
"DDInter860"
] | Omacetaxine mepesuccinate | Hepatitis B Vaccine (Recombinant) | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
4,
24,
1367
]
],
[
[
4,
63,
1083
],
[
1083,
24,
1367
]
],
[
[
4,
64,
1064
],
[
1064,
24,
1367
]
],
[
[
4,
24,
1480
],
[
1480,
24... | [
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases whe... | Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Trifluridine and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Omacetaxine mepesuccinate may lead to a major life threatening interac... |
DB00860 | DB14444 | 891 | 151 | [
"DDInter1513",
"DDInter924"
] | Prednisolone | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
891,
24,
151
]
],
[
[
891,
63,
66
],
[
66,
24,
151
]
],
[
[
891,
24,
1619
],
[
1619,
24,
151
]
],
[
[
891,
40,
1573
],
[
1573,
2... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that cou... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Prednisolone may cause a moderate i... |
DB00434 | DB00674 | 13 | 1,516 | [
"DDInter459",
"DDInter802"
] | Cyproheptadine | Galantamine | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sour... | Moderate | 1 | [
[
[
13,
24,
1516
]
],
[
[
13,
63,
475
],
[
475,
40,
1516
]
],
[
[
13,
24,
828
],
[
828,
40,
1516
]
],
[
[
13,
18,
6072
],
[
6072,
57... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Galantamine"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
... | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine (Compound) resembles Galantamine (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) resembles Galantamine (Compou... |
DB00346 | DB00938 | 472 | 455 | [
"DDInter44",
"DDInter1635"
] | Alfuzosin | Salmeterol | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Moderate | 1 | [
[
[
472,
24,
455
]
],
[
[
472,
24,
688
],
[
688,
63,
455
]
],
[
[
472,
6,
8374
],
[
8374,
45,
455
]
],
[
[
472,
21,
28722
],
[
28722,
... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
... | Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Alfuzosin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Salmeterol (Compound)
Alfuzosin (Compound)... |
DB11581 | DB11757 | 1,456 | 960 | [
"DDInter1926",
"DDInter994"
] | Venetoclax | Istradefylline | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process,. Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lym... | Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia. This region of the brain is highly in... | Major | 2 | [
[
[
1456,
25,
960
]
],
[
[
1456,
62,
1135
],
[
1135,
23,
960
]
],
[
[
1456,
24,
1499
],
[
1499,
24,
960
]
],
[
[
1456,
63,
86
],
[
86,
... | [
[
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Istradefylline"
]
],
[
[
"Venetoclax",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol... | Venetoclax may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Istradefylline
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine and Naldeme... |
DB01166 | DB01244 | 477 | 762 | [
"DDInter379",
"DDInter192"
] | Cilostazol | Bepridil | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United St... | Major | 2 | [
[
[
477,
25,
762
]
],
[
[
477,
63,
675
],
[
675,
40,
762
]
],
[
[
477,
6,
12523
],
[
12523,
45,
762
]
],
[
[
477,
21,
28698
],
[
28698,
... | [
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bepridil"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
],
[
"Dext... | Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene (Compound) resembles Bepridil (Compound)
Cilostazol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Bepridil (Compound)
Cilostazol (Compound) causes Insomnia (Side Effect) an... |
DB00445 | DB01132 | 322 | 1,130 | [
"DDInter655",
"DDInter1472"
] | Epirubicin | Pioglitazone | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Moderate | 1 | [
[
[
322,
24,
1130
]
],
[
[
322,
7,
4698
],
[
4698,
46,
1130
]
],
[
[
322,
18,
1870
],
[
1870,
46,
1130
]
],
[
[
322,
18,
2475
],
[
2475,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
]
],
[
[
"Epirubicin",
"{u} (Compound) upregulates {v} (Gene)",
"GPC1"
],
[
"GPC1",
"{u} (Gene) is upregulated by {v} (C... | Epirubicin (Compound) upregulates GPC1 (Gene) and GPC1 (Gene) is upregulated by Pioglitazone (Compound)
Epirubicin (Compound) downregulates MYC (Gene) and MYC (Gene) is upregulated by Pioglitazone (Compound)
Epirubicin (Compound) downregulates RGS2 (Gene) and RGS2 (Gene) is downregulated by Pioglitazone (Compound)
Epir... |
DB00794 | DB08912 | 759 | 1,040 | [
"DDInter1521",
"DDInter462"
] | Primidone | Dabrafenib | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
759,
24,
1040
]
],
[
[
759,
6,
3486
],
[
3486,
45,
1040
]
],
[
[
759,
18,
17017
],
[
17017,
57,
1040
]
],
[
[
759,
21,
28658
],
[
2865... | [
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Primidone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
... | Primidone (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Dabrafenib (Compound)
Primidone (Compound) downregulates CD320 (Gene) and CD320 (Gene) is downregulated by Dabrafenib (Compound)
Primidone (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Dabrafenib (Compound)
Primido... |
DB06228 | DB12095 | 792 | 179 | [
"DDInter1609",
"DDInter1760"
] | Rivaroxaban | Telotristat ethyl | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Moderate | 1 | [
[
[
792,
24,
179
]
],
[
[
792,
63,
79
],
[
79,
24,
179
]
],
[
[
792,
24,
214
],
[
214,
24,
179
]
],
[
[
792,
64,
1213
],
[
1213,
24,... | [
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
... | Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib a... |
DB05812 | DB09143 | 1,374 | 313 | [
"DDInter8",
"DDInter1701"
] | Abiraterone | Sonidegib | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Moderate | 1 | [
[
[
1374,
24,
313
]
],
[
[
1374,
63,
1559
],
[
1559,
23,
313
]
],
[
[
1374,
64,
478
],
[
478,
24,
313
]
],
[
[
1374,
24,
1478
],
[
1478,
... | [
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sonidegib"
]
],
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
... | Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a minor interaction that can limit clinical effects when taken with Sonidegib
Abiraterone may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a m... |
DB01208 | DB08899 | 945 | 129 | [
"DDInter1705",
"DDInter649"
] | Sparfloxacin | Enzalutamide | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Major | 2 | [
[
[
945,
25,
129
]
],
[
[
945,
64,
918
],
[
918,
1,
129
]
],
[
[
945,
6,
4973
],
[
4973,
45,
129
]
],
[
[
945,
21,
28703
],
[
28703,
... | [
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
]
],
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",
... | Sparfloxacin may lead to a major life threatening interaction when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Sparfloxacin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Enzalutamide (Compound)
Sparfloxacin (Compound) causes Pruritus (Side Effect) and Pruritus (Sid... |
DB09054 | DB09079 | 384 | 1,496 | [
"DDInter905",
"DDInter1296"
] | Idelalisib | Nintedanib | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis trea... | Moderate | 1 | [
[
[
384,
24,
1496
]
],
[
[
384,
63,
33
],
[
33,
24,
1496
]
],
[
[
384,
24,
1412
],
[
1412,
63,
1496
]
],
[
[
384,
64,
477
],
[
477,
... | [
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
],
[
... | Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol an... |
DB06262 | DB09082 | 1,354 | 659 | [
"DDInter606",
"DDInter1934"
] | Droxidopa | Vilanterol | Droxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism. It is approved for use in Japan and is currently in trials in the U.S. The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a def... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
1354,
24,
659
]
],
[
[
1354,
63,
1674
],
[
1674,
24,
659
]
],
[
[
1354,
1,
817
],
[
817,
24,
659
]
],
[
[
1354,
24,
1629
],
[
1629,
... | [
[
[
"Droxidopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Droxidopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[
... | Droxidopa may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Droxidopa (Compound) resembles Dopamine (Compound) and Dopamine may cause a moderate interaction that could... |
DB00015 | DB00078 | 582 | 1,172 | [
"DDInter1585",
"DDInter898"
] | Reteplase | Ibritumomab tiuxetan | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids p... | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | Major | 2 | [
[
[
582,
25,
1172
]
],
[
[
582,
23,
539
],
[
539,
62,
1172
]
],
[
[
582,
24,
578
],
[
578,
63,
1172
]
],
[
[
582,
25,
707
],
[
707,
... | [
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibritumomab tiuxetan"
]
],
[
[
"Reteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsic... | Reteplase may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Ibritumomab tiuxetan
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagr... |
DB01174 | DB08901 | 697 | 1,468 | [
"DDInter1442",
"DDInter1492"
] | Phenobarbital | Ponatinib | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
697,
24,
1468
]
],
[
[
697,
25,
478
],
[
478,
24,
1468
]
],
[
[
697,
6,
10083
],
[
10083,
45,
1468
]
],
[
[
697,
21,
28722
],
[
28722,... | [
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Niloti... | Phenobarbital may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Phenobarbital (Compound) binds ABCB11 (Gene) and ABCB11 (Gene) is bound by Ponatinib (Compound)
Phenobarbital (Compound) causes... |
DB00726 | DB00782 | 1,164 | 1,123 | [
"DDInter1876",
"DDInter1535"
] | Trimipramine | Propantheline | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Moderate | 1 | [
[
[
1164,
24,
1123
]
],
[
[
1164,
21,
28898
],
[
28898,
60,
1123
]
],
[
[
1164,
24,
537
],
[
537,
63,
1123
]
],
[
[
1164,
64,
1425
],
[
14... | [
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Trimipramine",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Ef... | Trimipramine (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Propantheline (Compound)
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken w... |
DB06292 | DB08886 | 549 | 637 | [
"DDInter474",
"DDInter126"
] | Dapagliflozin | Asparaginase Erwinia chrysanthemi | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-aspar... | Moderate | 1 | [
[
[
549,
24,
637
]
],
[
[
549,
63,
167
],
[
167,
24,
637
]
],
[
[
549,
62,
467
],
[
467,
24,
637
]
],
[
[
549,
24,
850
],
[
850,
24,... | [
[
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Dapagliflozin may cause a minor interaction that can limit clinical effects wh... |
DB01116 | DB11827 | 601 | 433 | [
"DDInter1872",
"DDInter669"
] | Trimethaphan | Ertugliflozin | A nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery. | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
601,
24,
433
]
],
[
[
601,
63,
251
],
[
251,
24,
433
]
],
[
[
601,
24,
885
],
[
885,
24,
433
]
],
[
[
601,
40,
762
],
[
762,
24,... | [
[
[
"Trimethaphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Trimethaphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
]... | Trimethaphan may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Trimethaphan may cause a moderate interaction that could exacerbate diseases when taken with Epoprost... |
DB00585 | DB11963 | 1,127 | 1,045 | [
"DDInter1309",
"DDInter465"
] | Nizatidine | Dacomitinib | A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers. | Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was devel... | Moderate | 1 | [
[
[
1127,
24,
1045
]
],
[
[
1127,
1,
1194
],
[
1194,
24,
1045
]
],
[
[
1127,
62,
109
],
[
109,
24,
1045
]
],
[
[
1127,
63,
883
],
[
883,
... | [
[
[
"Nizatidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacomitinib"
]
],
[
[
"Nizatidine",
"{u} (Compound) resembles {v} (Compound)",
"Ranitidine"
],
[
"Ranitidine",
"{u} may cause a modera... | Nizatidine (Compound) resembles Ranitidine (Compound) and Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Nizatidine may cause a minor interaction that can limit clinical effects when taken with Duloxetine and Duloxetine may cause a moderate interaction that could ... |
DB06603 | DB11003 | 39 | 748 | [
"DDInter1387",
"DDInter100"
] | Panobinostat | Anthrax vaccine | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
39,
24,
748
]
],
[
[
39,
64,
322
],
[
322,
24,
748
]
],
[
[
39,
25,
594
],
[
594,
24,
748
]
],
[
[
39,
25,
676
],
[
676,
63,
... | [
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epirubicin"
],
[
"E... | Panobinostat may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Panobinostat may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may cause a modera... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.